Gold prices edge higher on raised Fed rate cut hopes
Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals (NASDAQ:JAZZ), a company with impressive 92% gross margins and a "GREAT" financial health score according to InvestingPro, recently sold 6,500 ordinary shares of the company at a price of $144.25 each, totaling $937,625. This transaction, executed on March 3, 2025, was conducted under a pre-established Rule 10b5-1 trading plan. Following this sale, Cozadd’s direct ownership stands at 464,058 shares. The stock is currently trading near its 52-week high of $148.06, with analysis suggesting potential undervaluation.
In a separate transaction on February 27, 2025, Cozadd acquired 30,814 restricted stock units with no immediate monetary exchange. These units, granted under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan, are set to vest on March 5, 2026. Notably, management has been actively buying back shares, demonstrating confidence in the company’s future. Discover more insights about JAZZ and access detailed Pro Research Reports covering 1,400+ stocks on InvestingPro.
In other recent news, Jazz Pharmaceuticals reported its Q4 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $6.60 and revenue of $1.1 billion, both exceeding forecasts. The company also provided financial guidance for 2025, projecting revenue growth of 5% to reach between $4.15 billion and $4.4 billion. Needham analyst Ami Fadia increased the stock’s price target to $210, citing positive developments such as the Epidiolex settlement, which extends market exclusivity into the late 2030s. Meanwhile, RBC Capital Markets slightly reduced its price target for Jazz Pharmaceuticals to $178, maintaining an Outperform rating, while noting uncertainties in the company’s pipeline and leadership transition. Jazz Pharmaceuticals’ sleep franchise, particularly its Idiopathic Hypersomnia treatments, continues to perform strongly, and the company has achieved FDA approval for Xyhara. Despite a quieter pipeline, Jazz Pharmaceuticals is noted for its strong commercial execution and cash discipline. The company remains focused on strategic investments in neuroscience, oncology, and rare diseases as it navigates upcoming changes in leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.